Vutrisiran

home run

Pharma

Alnylam sees Amvuttra as potential standard of care in ATTR-CM

At the ESC conference, Alnylam presented data from a key trial which assessed Amvuttra as a treatment for transthyretin amyloid cardiomyopathy.

Kevin Dunleavy Aug 30, 2024 10:06am

Yvonne Greenstreet Alnylam

Alnylam scraps Amvuttra ATTR heart disease interim analysis

Oct 27, 2022 11:48am

Onpattro

Alnylam's high-stakes Onpattro heart trial posts partial win

Aug 3, 2022 10:22am

Amvuttra

Alnylam's Onpattro follow-up med wins FDA approval

Jun 14, 2022 9:00am